Section Arrow
AIM.NYSE-M
- AIM ImmunoTech
Quotes are at least 15-min delayed:2024/05/16 04:19 EDT
Last
 0.3996
+0.0152 (+3.95%)
Day High 
0.4098 
Prev. Close
0.3844 
1-M High
0.562 
Volume 
178.35K 
Bid
0.385
Ask
0.41
Day Low
0.38 
Open
0.4 
1-M Low
0.36 
Market Cap 
19.56M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.41 
20-SMA 0.42 
50-SMA 0.43 
52-W High 0.7487 
52-W Low 0.3201 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.60/-0.46
Enterprise Value
20.06M
Balance Sheet
Book Value Per Share
0.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
202.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 04:19 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.